KnolAIHealthcare and life sciences are producing scientific information at an unprecedented pace. Every year, millions of new publications emerge across clinical trials, real‑world studies, regulatory decisions, conference abstracts, and health economics research.
PienomialThe life sciences sector produces huge volumes of clinical, regulatory and scientific data. Most organisations find themselves struggling because their evidence lives in separate tools, databases, and team environments.
KnolForgeMost pharma organisations in 2026 are not short of AI tools. They have one platform for literature search, another for regulatory writing, a third for competitive monitoring, a standalone modelling tool for health economics, and a generic large language model that teams use informally for drafting and summarisation. Each tool solved a problem at the point of purchase. Together, they have created a new problem: fragmented intelligence, broken audit trails, and compounding governance risk.
Knolens SLRWe are living through a data paradox. We have access to more clinical information than at any point in human history, yet the ability to verify that information has never been more fragile.
PienomialThe pharmaceutical and life sciences sector is in a huge transition. You can't deny the efficiency AI offers, but here’s the sticking point: unlike most other industries, pharma can’t afford to rush. Every bit of evidence produced from trial data to value dossiers must survive intense scrutiny from regulators, HTA agencies, and global payers. So, the future isn't just about deploying AI; it's about being strategic and adopting truly compliant AI in healthcare.
Knolens SLRThe pharmaceutical industry has never stood still, but today, the pace of innovation and competition is redefining how clinical strategy must operate. The days of developing a drug in isolation, confident that the sheer science would secure market dominance, are long gone.
AI for drug developmentIn the high-stakes world of drug development, timing is everything. Traditionally, teams have treated pharmaceutical competitive intelligence as a monitoring function, something to look at once a study is underway or nearing commercialisation.
PienomialMarket Access teams work in rapidly evolving environments where payer demands, clinical changes and competition change rapidly. To build compelling value stories, teams must act as soon as information reaches them.
Knolens SLRHealth technology assessments, regulatory submissions, and evidence-based decision frameworks depend on comprehensive and systematically evaluated scientific literature.
AI in healthcareArtificial intelligence is no longer a futuristic concept; it is an operational reality. However, the deployment of AI in life sciences faces a unique hurdle that consumer tech does not: the zero-error mandate. When a recommendation engine suggests the wrong movie, it’s an annoyance.
systematic literature reviewIn the complex landscape of Health Economics and Outcomes Research (HEOR) and Market Access, the systematic literature review is the bedrock of evidence.
AI for drug developmentFor years, AI adoption in drug development has outpaced the regulatory frameworks governing it, leaving sponsors to build AI-powered trial design capabilities on data infrastructure that no agency had formally evaluated.
Knolens SLRIn the high-stakes poker game of drug development, playing your hand without watching the other players isn’t bold, it’s reckless.
AI for drug developmentThe structural transformation in clinical trial development began with a tool so routine that its constraints went unquestioned.
KnolPersonaThe EU Joint Clinical Assessment (JCA) regulation became mandatory for these product classes, creating a single EU-level clinical assessment that runs in parallel with the EMA regulatory review, not after it. For pharma teams accustomed to beginning HTA dossier preparation following regulatory approval, this is a strategic and operational discontinuity of the first order.
systematic literature reviewThe pharma industry sits right at the intersection of breakthrough science and ironclad regulation. There’s practically zero room for error. AI promises to turbocharge drug discovery, speed up clinical trials, and simplify those exhausting regulatory submissions. But here’s the thing: there's a huge chasm between general-purpose AI and the truly reliable AI for life sciences needed for GxP environments.
Systematic Literature ReviewsIn the modern life sciences landscape, data is no longer the bottleneck; the bottleneck is synthesis. Pharmaceutical companies, specifically Health Economics and Outcomes Research (HEOR)
KnolAIClinical development teams spend 40+ hours per month manually extracting competitor trial data, time that could be spent on strategic planning. Yet 62% of protocol amendments stem from avoidable competitive blind spots identified too late.
KnolScapesIn the pharmaceutical industry, the only certainty is uncertainty. Yet, decisions involving billions of dollars and years of development are often made based on linear assumptions that fail to account for the dynamic reality of the market.
PienomialThe pharmaceutical industry has a timing problem. We spend years developing a molecule. We spend months designing a clinical trial. We spend weeks compiling a systematic literature review. But the market does not wait for our timeline.
KnolScapeProtocol amendments cost pharma companies $535K on average and delay trials by 6+ months. Yet 40% of amendments stem from avoidable design flaws that benchmarking could have caught.
KnolScapesThe field of drug development is entering a new era characterised by data-driven decision-making, predictive modelling and advanced computational science. Over the last 20 years, costs to bring a new therapy to market have increased by close to a tenfold increase, typically referred to as Eroom’s Law.
KnolAIConsider this scenario: an advisory board meeting is scheduled in three weeks. A payer wants a rapid-turnaround evidence summary on your asset's comparative effectiveness versus the current standard of care. Your HEOR team is still three weeks deep into a manual literature review that will not be complete for another month.
competitive intelligenceIn the pharmaceutical industry, where a single competitor's Phase III readout can reshape a multi-billion dollar market overnight, the difference between knowing first and knowing last is not a matter of competitive preference. It is a matter of commercial survival.
AI Software for HealthcareFor the better part of a century, the assumption has been this: proprietary data is a competitive advantage, and competitive advantage is never shared.
clinical trial design softwareEvery transformative shift in clinical trial design begins with a question that challenges an assumption so embedded that it is rarely examined. For decades, that assumption has been this: every trial needs a live placebo group.
KnolScapePeople love to compare drug development to a marathon. It sounds noble, right? The long haul, the endurance, the solitary push.
AI for drug developmentThe pharmaceutical landscape in 2026 is defined by a paradox: we have more data than ever before, yet the path to a successful approved therapy remains fraught with costly delays.
KnolAiAny Transformational change in the pharmaceutical research field often starts with the realisation that the industry’s evidentiary foundation is inherently fragmented.
Private by design. Speaks your language. Proven at scale
